These six stocks span numerous sectors, providing investors with opportunities in both growth and dividend yield.

Under the deal, cash-paying patients can access a month’s supply of Wegovy through the Danish drugmaker’s Novocare pharmacy for $299. The one-time price will also be available through Novo’s other ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

Novo Nordisk has bounced back from a sour ending to its Hims & Hers partnership, revealing a new deal with WeightWatchers to ...

Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1. Ciara Lee reports.

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Novo Nordisk cut ties with Hims & Hers, accusing the telehealth firm of promoting Wegovy copycat versions of the weight-loss ...

Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.

Novo Nordisk continues to expand its partnerships with telehealth companies to broaden access to its blockbuster weight loss ...